From nucleation to widespread propagation: A prion-like concept for ALS  by Maniecka, Zuzanna & Polymenidou, Magdalini
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Propagation  of  pathological  protein  assemblies  via  a prion-like  mechanism  has been suggested  to  drive
neurodegenerative  diseases,  such  as  Parkinson’s  and Alzheimer’s.  Recently,  amyotrophic  lateral  sclerosis
(ALS)-linked  proteins,  such  as SOD1,  TDP-43  and  FUS  were  shown  to  follow  self-perpetuating  seededeywords:
LS
rion-like transmission
tress granules
DP-43
US
9orf72
aggregation,  thereby  adding  ALS  to the  group  of  prion-like  disorders.  The  cell-to-cell  spread  of  these
pathological  protein  assemblies  and  their pathogenic  mechanism  is  poorly  understood.  However,  as  ALS
is a non-cell  autonomous  disease  and  pathology  in  glial  cells  was  shown  to  contribute  to  motor  neuron
damage,  spreading  mechanisms  are  likely  to  underlie  disease  progression  via  the interplay  between
affected  neurons  and  their  neighboring  glial  cells.
©  2015  The  Authors.  Published  by Elsevier  B.V. This  is  an open  access  article  under  the  CC BY  license. Prions and prion-like events in neurodegeneration
Neurodegenerative diseases, such as Alzheimer’s or Parkinson’s
isease, are among today’s major public health issues. Despite
ecades of extensive research on the molecular mechanisms driv-
ng neurodegeneration, no consensus has yet emerged, thus making
t more challenging to develop effective therapies. A common
eature of neurodegenerative diseases is the accumulation of mis-
olded proteins in affected regions of the central nervous system
CNS). The main protein component of these pathological deposits
ay  be unique for each disorder, e.g. -synuclein in Parkinson’s
isease (PD) or -amyloid in Alzheimer’s disease (AD). More-
ver, some conditions are characterized by accumulation of more
han one misfolded protein. For instance, pathological tau and
-amyloid are the primary pathologies in AD, but secondary
athologies, such as TDP-43 (Amador-Ortiz et al., 2007; Uryu et al.,
008) and -synuclein (Hamilton, 2000; Higashi et al., 2007), also
ccur in ∼30–40% of AD patients. In addition, one type of aggregated
rotein may  be observed in multiple disorders, such as TDP-43,
hich is found abundantly in the pathogenic inclusions of patients
ith amyotrophic lateral sclerosis (ALS) and frontotemporal lobar
egeneration (FTLD) (Arai et al., 2006; Neumann et al., 2006), but
lso many other diseases, including a fraction of AD and PD cases
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(Banks et al., 2008; Lagier-Tourenne et al., 2010; Walker et al.,
2014).
In the recent years, increasing evidence supports a common
mechanism driving neurodegeneration in many clinically diverse
conditions. This pathogenic mechanism involves formation of aber-
rant protein aggregates, which is propagated in a self-templating
manner (Fig. 1A). Indeed, misfolded protein assemblies have been
shown to act as seeds of aggregation that can sequester their native
isoforms and convert them into pathological molecules, thereby
growing in size. Subsequent fragmentation of the aggregates and
repetition of the cycle leads to ampliﬁcation of the pathological
state within one cell, as well as through the nervous system via the
release of seeds to the extracellular space, uptake by the neighbor-
ing cells and repetition of the propagation cycle.
This mechanism, resembles the replication of infectious prions,
and is therefore often termed “prion-like” (Goedert et al., 2010;
Guo and Lee, 2014; Jucker and Walker, 2013; Polymenidou and
Cleveland, 2011, 2012). Prion diseases, also called transmissible
spongiform encephalopathies, are neurological disorders, which
unlike any other human neurodegenerative disease, can be trans-
mitted between individuals. The infectious agent is the prion, which
consists only of misfolded pathogenic protein (Prusiner, 1982).
Besides infectious etiology, prion diseases, like other neurodegen-
erative disorders, can have sporadic or familial origin. In the latter,
heritable mutations occur in the PRNP gene encoding the cellular
prion protein. The disease mechanism is based on the conver-
sion of the normal cellular isoform of the prion protein, PrPC, to a
misfolded highly aggregative form, PrPSc, triggering a widespread
misfolding and ﬁbril formation across the nervous system in a
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Fig. 1. Prion-like propagation mechanisms. (A) In the classical view of prion-like ampliﬁcation of pathological protein conformation, the misfolded protein interacts with its
native  counterpart and converts it into a pathological molecule. This aberrant aggregate elongates by recruitment and conversion of further native protein, which produces a
highly  ordered seed of aggregation. The latter eventually fragments, resulting in multiple seeds, which induce next cycles of seeded nucleation and amplify the pathological
protein aggregation and disease phenotype. (B) For RNA-binding proteins with prion-like domains, such as TDP-43 and FUS, aggregate nucleation may be initiated within
t omple
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ihe  stress granules, which are highly dynamic and strictly regulated protein–RNA c
NA-binding and conformational change and results in the increase of local protei
ellular  stress conditions, the highly concentrated RNA-binding proteins in stress gr
ggregates.
elf-perpetuating manner (Aguzzi, 2009; Aguzzi and Polymenidou,
004; Aguzzi and Rajendran, 2009). Indeed, mice lacking the prion
rotein are completely resistant to prion disease (Bueler et al.,
993). The pathology of prion diseases is characterized by protein
ggregation, neuronal loss, gliosis and spongiform degeneration
Aguzzi and Polymenidou, 2004). Moreover, the misfolded prion
rotein was shown to acquire several different structural con-
ormations, referred to as strains, which lead to development of
arious disease phenotypes with distinct histopathological sig-
atures, incubation periods and severity of disease progression
Aguzzi et al., 2007).
The recognition that pathological aggregates of -amyloid, tau,
-synuclein and others behave in a prion-like manner has major
mplications for disease initiation and progression (Goedert et al.,
010; Guo and Lee, 2014; Jucker and Walker, 2013; Polymenidou
nd Cleveland, 2011, 2012). Indeed, it has been suggested that
ost neurodegenerative disorders spread in a spatiotemporal
ashion through mechanisms involving the seeded aggregation
f pathogenic proteins, which trigger neurotoxicity and eventu-
lly neuronal cell death (Aguzzi, 2009; Aguzzi and Rajendran,
009; Goedert et al., 2010; Polymenidou and Cleveland, 2011,
012). There is substantial evidence supporting this hypothesis, as
myloid- (Meyer-Luehmann et al., 2006), tau (Clavaguera et al.,
009; Liu et al., 2012; Nonaka et al., 2010), and -synuclein (Luk
t al., 2012; Masuda-Suzukake et al., 2013; Nonaka et al., 2010;
olpicelli-Daley et al., 2011) aggregates were able to induce native
rotein misfolding and cell-to-cell transmission, both in vitro and
n vivo.
. Terminology
While recent evidence indicates that the molecular mechanisms
nderlying the replication of prions is fundamentally the same with
he mechanisms propagating pathological aggregates in other neu-
odegenerative diseases, there is one substantial difference. There
s currently no evidence that any other human neurological disor-
er, besides prion diseases, can be transmitted from one individual
o another (Irwin et al., 2013). Therefore a speciﬁc terminology is
eeded to distinguish them from prion diseases. Since the scientiﬁc
ommunity has not fully settled on this terminology, we deﬁne our
nterpretation of the most commonly used terms below.xes forming in cellular stress conditions. The formation of stress granules involves
entration. In disease, potentially as a consequence of yet uncharacterized chronic
 may  transform into pre-inclusions and eventually convert into irreversible protein
The self-perpetuating propagation of misfolding and aggre-
gation, resembling that of prion ampliﬁcation, is referred to as
‘prion-like’ mechanism. The term ‘seeding’ is used to describe the
templated aggregation and conversion of a large amount of natively
folded protein into pathological conformation, via the introduction
of minute amounts of preformed aggregates. Although, seeding is
mostly referred to in vitro assays on puriﬁed proteins, it could be
extended to mean the same type of molecular events occurring
within a cell. ‘Nucleation’ refers to the initial phase of the seeding
process, namely formation of the seed of aggregation. The propa-
gation of aggregates within one organism, via cellular connections,
exo/endocytosis mechanisms and possibly other, yet unclariﬁed
events, is often called ‘cell-to-cell spreading’. Lastly, the term ‘pri-
onoid’ has been coined to differentiate the pathological proteins
causative for prion-like diseases from the bona ﬁde infectious prion
(Aguzzi, 2009).
Within the recent years exciting reports emerged, suggesting
that ALS-linked pathological proteins are indeed prionoids, as they
have the potential to seed and propagate their pathological confor-
mation through recruitment of native proteins. Consequently, one
major focus of ALS research today is the investigation of the role of
seeded aggregation mechanisms in ALS pathogenesis.
3. Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis is an adult-onset neurodegen-
erative disorder, which is characterized by rapidly progressive
weakness and muscular wasting, leading to paralysis and death due
to respiratory failure within 1–5 years from disease onset (Ilieva
et al., 2009; Polymenidou et al., 2012). ALS is the most common
motor neuron disease that affects more than 1 in 100,000 individ-
uals each year. The major risk factor of ALS is age, as the disease
most commonly occurs between 40 and 60 years. However, there
are other environmental factors that increase the risk of developing
ALS, such as lifetime of intensive physical activity (Kiernan et al.,
2011; Scarmeas et al., 2002; Veldink et al., 2005), as in the case of
professional football players (Chio et al., 2005) or members of the
military (Weisskopf et al., 2005).
The majority of ALS cases (90%) presents spontaneous onset
without any evidence of inheritance, and is referred to as spo-
radic ALS (sALS). The remaining 10%, classiﬁed as familial ALS
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fALS), shows an apparent hereditary contribution and is linked
o dominant inheritance of mutations in several ALS-linked genes.
utations in the gene encoding copper/zinc superoxide dismu-
ase 1 (SOD1) were the ﬁrst identiﬁed genetic causes of ALS, which
ccount for 20% of fALS (Rosen et al., 1993). Subsequent generation
f transgenic mice and rats expressing ALS-causing SOD1 mutants
Bruijn et al., 1998; Gurney et al., 1994; Wong et al., 1995), which
emain the most faithful animal models for ALS, has focused atten-
ion to research aiming at deciphering the molecular mechanisms
n SOD1-linked ALS.
A shift of interest occurred many years later, with the recog-
ition that TAR DNA-binding protein of 43 kDa (TDP-43) is the
ajor component of ubiquitin-positive, cytoplasmic inclusions
ound abundantly in patients with sporadic ALS (Arai et al., 2006;
eumann et al., 2006). This discovery was rapidly followed by the
dentiﬁcation that mutations in the TARDBP gene cause ALS (Gitcho
t al., 2008; Kabashi et al., 2008; Sreedharan et al., 2008; Van Deerlin
t al., 2008; Yokoseki et al., 2008). A year later, mutations in another
NA/DNA-binding protein, referred to as fused in sarcoma (FUS) or
ranslocated in liposarcoma (TLS) (Kwiatkowski et al., 2009; Vance
t al., 2009) were shown to cause rare cases of familial ALS. Most
ecently, large expansions in an intronic hexanucleotide repeat
egion of an uncharacterized gene, called C9ORF72, were identi-
ed in ∼10% of all ALS cases, rendering it the most common genetic
ause of the disease (Renton et al., 2011; DeJesus-Hernandez et al.,
011). Furthermore, mutations in many other genes were shown
o cause familial forms of ALS (reviewed in Rademakers and van
litterswijk, 2013; Renton et al., 2014), which even though are
vidently rare, may  contribute to our understanding of disease
echanisms, especially as they point toward common pathways
ith other ALS-causing genes. Additionally, ALS was  considered for
any years to be a cell-autonomous disease that leads to a selec-
ive degeneration and death of upper and lower motor neurons.
owever, it is now established that other cell types, mainly the
eighboring glial cells, signiﬁcantly contribute to the progression
f ALS (reviewed in Ilieva et al., 2009). These discoveries of the
ast ∼10 years suggest that ALS is a heterogeneous and multifac-
orial disease, in which neuronal cell death can result from many
ifferent upstream triggers that potentially converge to common
ownstream mechanisms.
In this review we will focus on the genes that deﬁne the majority
f ALS, namely SOD1, TARDBP, FUS and C9ORF72. We  will discuss
he evidence that protein products originating from these genes
ave the potential to form pathological protein assemblies that may
mplify and spread their pathological conformation throughout the
ervous system in a prion-like manner.
.1. Superoxide dismutase 1 (SOD1)
SOD1 was the ﬁrst – and for a long time the only – protein
ound to be involved in ALS pathogenesis (Rosen et al., 1993) and
ill now more than 170 ALS-linked mutations were identiﬁed in
he SOD1 gene. These mutations span the entire protein sequence
uggesting that any single nucleotide substitution is sufﬁcient to
rigger pathological changes in protein conformation. The depo-
ition of misfolded SOD1 caused by SOD1 mutations account for
pproximately 20% of fALS.
SOD1 is a 153 amino acid enzymatic protein that plays a
ole in scavenging free superoxide radicals in the body. Under
ative conditions, SOD1 forms a stable homodimer (Fig. 2A) that
s primarily diffused in the cytoplasm (Crapo et al., 1992), but
as also found to localize within the mitochondrial intermem-
rane space (Higgins et al., 2002; Okado-Matsumoto and Fridovich,
001). ALS-causing mutations lead to instability of the homodimer
nd consequently trigger misfolding of SOD1 and its accumula-
ion within cells (Fig. 2B). Multiple toxic properties acquired by Research 207 (2015) 94–105
such SOD1 deposits, rather than disruption of normal enzymatic
function of the protein, mediate neurotoxic pathways leading to
neurodegeneration and neural cell death in ALS (Ilieva et al., 2009).
For instance, pathogenic SOD1 may  cause postsynaptic neurotox-
icity due to misregulation of synaptic glutamate clearance, leading
to accumulation of glutamate and subsequent glutamate-induced
excitotoxicity (Bruijn et al., 1997; Rothstein et al., 1995). Aggre-
gated SOD1 has also been shown to induce ER stress through its
concentration in the ER lumen or association with the ER mem-
branes and interference in the ER-associated degradation (ERAD),
a process important for elimination of misfolded proteins (Kikuchi
et al., 2006; Nishitoh et al., 2008). Additionally, mutant SOD1 has
been suggested to impair normal proteasome function by inhibition
of the degradation pathways responsible for removal of abnor-
mal  proteins from the cell (Bendotti et al., 2012). Other reported
mechanisms involve mitochondrial damage, based on observa-
tion of an aberrant morphology and dysfunction of mitochondria
caused by mutant SOD1 deposition on the mitochondrial mem-
branes (Igoudjil et al., 2011; Vande Velde et al., 2008). Furthermore,
pathogenic SOD1 may  be secreted from affected cells and therefore
induce extracellular toxicity, modulate activation of the neighbor-
ing microglia and consequently increase the rate of neuronal cell
death (Ilieva et al., 2009).
While all mechanisms mentioned above are likely to contribute
to the pathogenesis of SOD1-linked ALS, the challenge now is to
identify which one(s) are indeed triggering the disease and which
are merely consequences of motor neuron death.
3.2. TAR DNA-binding protein of 43 kDa (TDP-43)
The identiﬁcation of TDP-43 as the major component of
ubiquitin-positive, cytoplasmic inclusions in patients with ALS
(Arai et al., 2006; Neumann et al., 2006) was a turning point in
ALS research. Soon after this discovery, several dominant muta-
tions in the TARDBP gene, which encodes TDP-43, were found to be
causative for familial ALS (∼4–5% of cases) and were also identiﬁed
in rare (∼1%) sporadic cases (Gitcho et al., 2008; Kabashi et al., 2008;
Sreedharan et al., 2008; Van Deerlin et al., 2008; Yokoseki et al.,
2008). These ﬁndings strongly suggest that pathological forms of
TDP-43 could directly induce neurotoxic pathways leading to neu-
rodegeneration. TDP-43 pathogenic aggregates are now recognized
as a characteristic feature of the majority (∼97%) of ALS patients.
Interestingly, these inclusions are absent in familial ALS cases with
SOD1 mutations (Mackenzie et al., 2007), which implies that differ-
ent upstream mechanisms drive neurodegeneration in TDP-43 and
SOD1 proteinopathies.
TDP-43 is a 414 amino acid protein that is highly conserved
and belongs to the ribonucleoprotein family. TDP-43 contains two
RNA recognition motifs (RRM1 and RRM2) that are evolutionar-
ily conserved and are involved in nucleic acid binding (Fig. 2A).
The C-terminal domain, which was shown to be highly aggregation
prone, contains a glycine-rich region important for protein inter-
actions. TDP-43 also contains a nuclear localization signal (NLS)
and a nuclear export signal (NES), which allow the shuttling of
TDP-43 between the nucleus and the cytoplasm. While in healthy
cells, TDP-43 localizes predominantly to the nucleus, in affected
neurons and glial cells, it mislocalizes to the cytoplasm, where it
forms pathogenic inclusions (Fig. 2B). This protein redistribution
and cytoplasmic aggregation prevents TDP-43 from returning to the
nucleus, leading to its nuclear clearing (Arai et al., 2006; Igaz et al.,
2008; Neumann et al., 2006; Van Deerlin et al., 2008). Moreover,
disease-associated TDP-43 presents a certain biochemical signa-
ture characterized by polyubiquitination, hyperphosphorylation
and proteolytic cleavage (Arai et al., 2006; Neumann et al., 2006).
The latter gives rise to highly aggregative C-terminal fragments
that are deposited in the cytoplasm along with the full-length
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Fig. 2. Summary of current evidence for prion-like propagation of ALS-linked proteins. (A) Protein structure: crystal structure of SOD1 homodimer (Auclair et al., 2013);
ribbon  representation of RNA-binding domain of TDP-43 in complex with RNA molecule (Lukavsky et al., 2013). Ribbon representation of RNA-binding domain of FUS (Liu
et  al., 2013). The structures of FUS protein and C9ORF72 dipeptide-repeat proteins have not been yet resolved. (B) Pathology: SOD1 cytoplasmic inclusions in motor neurons
of  the spinal cord from ALS patient with hSOD1A4V mutation (Kerman et al., 2010); ubiquitin-positive cytoplasmic inclusions of pathogenic TDP-43 in the spinal cord of
an  ALS patient (Arai et al., 2006); FUS cytoplasmic inclusions with granular morphology in lower motor neurons of fALS patient with FUSA521C mutation (Mackenzie et al.,
2010); cytoplasmic inclusions of dipeptide repeat proteins from the characteristic TDP-43-negative inclusions in C9ORF72 patients (Mori et al., 2013). (C) Seeded aggregation
in  vitro: SOD1: spontaneous and self-seeded aggregation reactions (in absence or presence of preformed SOD1 ﬁbrils, respectively) of wild type SOD1 protein. Addition of
SOD1  seeds signiﬁcantly increased aggregation kinetics (Chia et al., 2010); TDP-43: seeded aggregation of refolded C-terminal fragment of TDP-43 (TDP-43-Cterm) using
preformed TDP-43-Cterm aggregates as seeds. Without addition of seeds, TDP-43 did not form aggregates (Furukawa et al., 2011); FUS: seeded aggregation reaction of wild
type  FUS protein with and without addition of preformed mutant FUS aggregates as seeds. In the absence of seeds, the wild type FUS did not form aggregates (Nomura et al.,
2014). (D) Seeded aggregation in cell culture: SOD1: transiently transfected cells expressing mutant SOD1 tagged with GFP were inoculated with exogenous ﬂuorescently
modiﬁed mutant SOD1 aggregates. The endogenously expressed mutant SOD1 was evenly distributed in untreated cells. In contrast, upon treatment with exogenous SOD1
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oggregates, it formed inclusions that co-localized with the seeds (Münch et al., 2011
r  full length TDP-43, both HA tagged, were transduced with ﬂuorescently modiﬁed
f  endogenous proteins co-localized with aggregates used as seeds (Furukawa et al
DP-43 (Igaz et al., 2008; Neumann, 2009). Importantly, the major-
ty of ALS-linked missense mutations is localized in the C-terminal
lycine-rich domain (Lagier-Tourenne et al., 2010; Ling et al., 2013)
nd was shown to signiﬁcantly increase the aggregation propensity
f TDP-43 (Guo et al., 2011; Johnson et al., 2009).
.3. Fused in sarcoma (FUS) or translocated in liposarcoma (TLS)
Soon after the identiﬁcation of TDP-43, ALS-causing mutations
ere found in another DNA/RNA-binding protein, named FUS, also
eferred to as TLS (Kwiatkowski et al., 2009; Vance et al., 2009).
issense mutations in the FUS gene account for approximately 4%
f fALS cases and rare sporadic cases (Kwiatkowski et al., 2009;-43: transiently transfected cells expressing a truncated C-terminal form of TDP-43
nous aggregates, composed of a C-terminal form of TDP-43. Intracellular inclusions
).
Vance et al., 2009), some of which present with juvenile onset and
unusually rapid disease progression (Baumer et al., 2010; Yan et al.,
2010; Zou et al., 2013).
FUS is a 526 amino acid long ribonucleoprotein that binds
nucleic acids through its C-terminal part, which comprises an RNA
recognition motif (RRM), two glycine–arginine-rich motifs and a
zinc ﬁnger domain. The N-terminal part, which shows high aggre-
gation propensity, contains a glycine-rich region and a domain
enriched in glutamine, glycine, serine, and tyrosine residues (Sun
et al., 2011). FUS contains NLS and NES sequences, which allow
its shuttling between the nucleus and the cytoplasm, suggest-
ing that FUS is involved in RNA metabolism pathways that take
place in both cellular compartments (Lagier-Tourenne et al., 2010).
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evertheless, FUS predominantly localizes to the nucleus of healthy
ells, whereas in ALS patients with FUS mutations, pathological
rotein is redistributed to the cytoplasm of affected cells where it
ccumulates and aggregates (Fig. 2B). This mislocalization leads to
artial loss of nuclear protein (Mackenzie et al., 2010; Vance et al.,
009), similarly to TDP-43 pathology. The majority of FUS muta-
ions are clustered in the NLS sequence, which is embedded within
he highly conserved extreme C-terminus (Lagier-Tourenne et al.,
010; Ling et al., 2013). These mutations were shown to enhance
ytoplasmic localization of FUS (Dormann et al., 2010; Ito et al.,
011), rather than its aggregation propensity (Dormann et al., 2010;
un et al., 2011). Strikingly, while the pathogenic FUS aggregates
re immunoreactive for p62 and ubiquitin, in contrast to the char-
cteristic pathological signature of most ALS cases, FUS inclusions
re TDP-43-negative (Suzuki et al., 2010; Tateishi et al., 2010; Vance
t al., 2009).
.4. TDP-43 and FUS pathogenic mechanisms
The mutual exclusion of TDP-43 and FUS pathology, in combi-
ation with the high structural and functional similarity of the two
roteins, suggest that they mediate independent initiation steps,
hich could eventually lead to activation of common downstream
athways. The latter may  result either from loss of their normal
uclear function, because of protein redistribution and aggregation
n the cytoplasm, or from gain of toxic function, due to deposition
f the misfolded protein assemblies in the cytoplasm. It is impor-
ant to note that these two mechanisms are not mutually exclusive
nd likely cause motor neuron degeneration in conjunction (Lagier-
ourenne et al., 2010; Ling et al., 2013; Polymenidou et al., 2012).
The loss of normal TDP-43 or FUS function is most likely linked
o the central role that each protein plays in RNA maintenance and
rocessing. Indeed, both proteins are involved in multiple steps
f RNA metabolism, from transcription regulation and pre-mRNA
aturation, to mRNA transport, translation and microRNA bio-
enesis (Lagier-Tourenne et al., 2010; Polymenidou et al., 2012).
ovel approaches that combine cross-linking, immunoprecipitat-
on with high-throughput sequencing have shown that TDP-43
Polymenidou et al., 2011; Tollervey et al., 2011) and FUS (Lagier-
ourenne et al., 2012; Rogelj et al., 2012) bind an overwhelming
umber of RNA targets in the adult mouse and human brain, pre-
enting an extremely broad spectrum of possible aberrant TDP-43
nd FUS functions. While it is difﬁcult to specify which of them are
ssential to trigger neurodegeneration in ALS, given their apparent
utually exclusive role in disease, an attractive approach is the def-
nition of common TDP-43 and FUS RNA targets. Indeed, although
DP-43 and FUS bind a distinct spectrum of RNAs, they both showed
igh preference for mRNAs derived from genes with exception-
lly long introns (Lagier-Tourenne et al., 2012; Polymenidou et al.,
011). Importantly, 45 common TDP-43 and FUS RNA targets, the
ajority of which are important for normal neuronal function,
re signiﬁcantly downregulated upon depletion of either TDP-43
r FUS in the adult mouse brain and in cultured human neurons
Lagier-Tourenne et al., 2012; Polymenidou et al., 2011). High abun-
ance in the brain of these long-intronic genes (Ameur et al., 2011;
olymenidou et al., 2011), which are bound with very high afﬁn-
ty by both TDP-43 and FUS, presents a possible explanation of why
eurons are mostly susceptible to ALS pathogenic processes. More-
ver, a recent study showed that ALS-linked mutations impair the
ransport of TDP-43-containing RNA granules to distal neuronal
ompartments (Alami et al., 2014), suggesting another important
ole of TDP-43, whose disruption in ALS may  lead to neuronal mal-
unction. It remains to be seen whether FUS plays a similar role
n neuronal RNA transport and whether this process is affected
n disease. Furthermore, FUS and TDP-43 proteins were found to
hysiologically interact, and ALS-linked mutations in TARDBP gene Research 207 (2015) 94–105
seem to enhance this interaction (Ling et al., 2010). This adds yet
another indication for convergence of TDP-43 and FUS-mediated
pathogenic pathways.
The study of the direct toxicity of TDP-43 and FUS aggregates has
been compromised by the unfortunate lack of cellular and animal
models that faithfully recapitulate protein aggregation (Laferriere
and Polymenidou, 2015). Consequently, it remains unclear whether
TDP-43 and FUS cytoplasmic aggregates are a primary cause of ALS,
an inert byproduct of the disease process, or even the result of a
protective cellular response to neurodegeneration. Elegant studies
with sophisticated imaging technologies in cultured neurons sug-
gested that increased cytoplasmic, but not aggregated TDP-43 is
neurotoxic (Barmada et al., 2010, 2014). Moreover, this toxicity is
enhanced by an ALS-linked mutation (Barmada et al., 2010) and can
be ameliorated by TDP-43 clearance via activation of autophagy
(Barmada et al., 2014). These ﬁndings, in combination with the
prion-like ampliﬁcation of pathology described below, suggest
that, at least a part of the TDP-43 and FUS protein aggregates are
likely to be – directly or indirectly – neurotoxic. Therefore, further
studies are desperately needed to better characterize the disease-
associated protein assemblies, as well as to deﬁne their potential
neurotoxic properties.
3.5. Chromosome 9 open reading frame 72 (C9ORF72)
One of the most exciting discoveries in the ALS ﬁeld was the
identiﬁcation of intronic hexanucleotide repeat expansions in the
C9ORF72 gene of ALS patients, which is now recognized as the
most frequent genetic cause of ALS accounting for ∼40% of fALS
and ∼7% of sALS cases (DeJesus-Hernandez et al., 2011; Gijselinck
et al., 2012; Majounie et al., 2012; Renton et al., 2011). In healthy
individuals, the repeat length is shorter than 25–30 units, whereas
in C9ORF72 ALS patients, the number of repeats can expand to
700 repeats or more, with some patients carrying extremely long
repeats of >3000 units (DeJesus-Hernandez et al., 2011; Gijselinck
et al., 2012; van Blitterswijk et al., 2013). C9ORF72-linked ALS
cases show a complex pathological signature, which besides the
typical TDP-43 aggregation, is characterized by p62-positive and
TDP-43-negative ubiquitinated inclusions in the cerebellar and hip-
pocampal regions (Al-Sarraj et al., 2011; DeJesus-Hernandez et al.,
2011; Troakes et al., 2012), which are usually free of pathology
in non-C9ORF72 ALS (Geser et al., 2008, 2009). These inclusions
contain one of ﬁve different aggregating dipeptide-repeat (DPR)
proteins, namely poly-(Gly-Ala), poly-(Gly-Pro), poly-(Gly-Arg),
poly-(Pro-Arg) and poly-(Pro-Ala) (Ash et al., 2013; Mori et al.,
2013; Zu et al., 2013). These DPR proteins are generated by an
unconventional type of translation, called repeat-associated non-
ATG (RAN) translation (Zu et al., 2011), which operates on sense
(Ash et al., 2013; Mori et al., 2013) and antisense (Zu et al.,
2013) transcripts originating from the hexanucleotide repeat RNA.
Moreover, hexanucleotide repeats themselves were also found to
accumulate in nuclear RNA foci in neurons (DeJesus-Hernandez
et al., 2011) and glial cells (Lagier-Tourenne et al., 2013) of C9ORF72
ALS patients (Fig. 1B).
Repeat expansions have been previously reported to disrupt
RNA metabolism in other neurodegenerative diseases (Ranum and
Cooper, 2006). Therefore, C9ORF72, additionally to FUS and TDP-43,
has drawn even more attention to research aiming to under-
stand the role of potential RNA misregulation in ALS (Donnelly
et al., 2013; Polymenidou et al., 2012). The C9ORF72 gene itself
is poorly characterized and the physiological role of encoded
protein remains to be determined. However, ALS-associated hex-
anucleotide repeat expansions result in reduced levels of C9ORF72
RNA (DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012), either
due to the inactivation of the repeat-containing allele via promoter
hypermethylation (Xi et al., 2013), or transcriptional abortion of
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epeat RNAs (Haeusler et al., 2014). The lower C9ORF72 RNA and the
esulting reduced protein levels may  be insufﬁcient for its normal
unction, a phenomenon known as haploinsufﬁciency. Moreover,
he RNA hexanucleotide foci may  be directly toxic by acquiring
omplex secondary structures, such as G-quadruplexes and hair-
ins and by binding essential proteins, such as nucleolin, whose
equestration leads to nucleolar stress and other downstream
efects (Haeusler et al., 2014). Lastly, while the role of DPRs in the
athogenesis of C9ORF72 ALS remains unclear, recent studies have
hown that DPRs can confer toxicity in cultured cells, via interfer-
ng with RNA biogenesis (Kwon et al., 2014) and protein trafﬁcking
May  et al., 2014).
. Self-propagation of protein misfolding and aggregation
An increasing number of reports suggest that the main pro-
ein products deﬁning ALS pathology described above, can behave
n a prion-like manner, both in vitro and in cell culture (Fig. 2).
hile most of the proteins that misfold and accumulate in
eurodegeneration, including TDP-43 and FUS, are intrinsically
ggregation-prone, SOD1 is an exception to this rule. Wild type
OD1 is structurally one of the most stable proteins, which may
xplain why no bona ﬁde protein inclusions of wild type SOD1 have
een, unequivocally, described in human patients (Brotherton et al.,
012; Kerman et al., 2010), despite claims of abnormal, cytoplas-
ic  SOD1 immunoreactivity in a subset of sporadic ALS patients
Bosco et al., 2010). Nevertheless, pure, recombinant, wild type
OD1 can form ﬁbrils spontaneously, while conditions that dis-
upt its stable dimer, such as reducing agents or high temperature,
ccelerate the aggregation reaction (Chia et al., 2010; Münch et al.,
011). Also, similarly to TDP-43 (Guo et al., 2011; Johnson et al.,
009), ALS-linked mutations in SOD1 promote aggregation (Chia
t al., 2010; Prudencio et al., 2009). In contrast, most of the ALS-
inked FUS mutations are localized in the NLS and do not inﬂuence
ggregation per se,  but rather promote redistribution of FUS to
he cytoplasm (Dormann et al., 2010; Ito et al., 2011; Sun et al.,
011), which consequently may  initiate its aggregate nucleation.
he high propensity of TDP-43 and FUS to aggregate is linked to
he presence of a glycine-rich domain in both proteins, namely in
he N-terminal part of FUS (amino acids 1–239) and the C-terminal
art of TDP-43 (amino acids 274–414). Such domains, which are
requently found in RNA-binding proteins, have similar amino acid
omposition with yeast prion proteins and are therefore also called
prion-like” (Cushman et al., 2010), or low complexity domains
Kato et al., 2012), and can acquire disordered structures upon
rotein folding (King et al., 2012).
In vitro studies demonstrated that even small amounts of aggre-
ated SOD1 (Chia et al., 2010), TDP-43 (Furukawa et al., 2011) or
US (Nomura et al., 2014) were able to induce misfolding and aggre-
ation of their corresponding natively folded protein, implicating
emplate-dependent propagation (Fig. 1C). The prion-like domains
f TDP-43 (Furukawa et al., 2011; Guo et al., 2011; Johnson et al.,
009; Nonaka et al., 2009) and FUS (Sun et al., 2011) apparently
ediate protein aggregation and contribute to their seeding ability.
ndeed, increased expression of the TDP-43 glycine-rich domain,
nduced protein accumulation and cell toxicity (Furukawa et al.,
011; Guo et al., 2011; Johnson et al., 2009; Liu-Yesucevitz et al.,
010; Pesiridis et al., 2011; Zhang et al., 2009). On the contrary,
eletion of the TDP-43 (Furukawa et al., 2011; Johnson et al., 2009),
r FUS (Sun et al., 2011) prion-like domains prevented aggregate
ormation, which indicates that these domains are required for efﬁ-
ient seeding. Importantly, the prion-like domain of TDP-43 is the
ain protein product forming the cytoplasmic inclusions in ALS
atients (Igaz et al., 2008; Neumann, 2009), and the majority of ALS-
inked mutations are localized mainly within this domain. While Research 207 (2015) 94–105 99
the above observations have focused attention to the C-terminal
part of TDP-43, two recent studies highlight the signiﬁcance of an
N-terminal segment for its function and aggregation. Indeed, the
N-terminal part of TDP-43 was  reported to regulate proper protein
folding and function such as splicing regulation, but is also neces-
sary for TDP-43 aggregation (Zhang et al., 2013). This unexpected
function is mediated by its unusual structural switch from a folded,
ubiquitin-like domain upon binding to single stranded DNA and in
low protein concentrations, to an unfolded and aggregation-prone
structure when protein concentrations are increased (Qin et al.,
2014).
FUS is characterized by even higher aggregation propensity
compared to SOD1 or TDP-43, as it was shown to spontaneously
aggregate into ﬁbrils in a cell-free system within minutes (Sun
et al., 2011). Aggregates reconstituted in vitro from recombinant
wild type or mutant SOD1 (Furukawa et al., 2013; Münch et al.,
2011) and TDP-43 (Furukawa et al., 2011) triggered aggregation of
endogenously expressed protein in cell culture (Fig. 2D). While this
has not yet been shown for FUS, it was recently reported that co-
expression of mutant and wild type FUS induces aggregation of the
otherwise soluble wild type FUS, albeit, this aggregation seems to
be conﬁned in the nucleus (Nomura et al., 2014), in contrast to what
is typically seen in ALS patients (Fig. 2B). Recently, the insoluble
TDP-43 aggregates derived from brain homogenates of ALS patients
were shown to seed protein misfolding and accumulation in TDP-
43 transfected cultured cells (Nonaka et al., 2013). Importantly, the
induced TDP-43 (Nonaka et al., 2013) and SOD1 (Grad et al., 2011;
Münch et al., 2011) aggregates persisted within cells when the orig-
inal pathogenic seed was no longer present. Therefore, the newly
induced aggregates can act as new misfolding templates and exhibit
properties consistent with prion-like propagation.
Although several laboratories are currently studying these
prion-like phenomena in animals, until now, the seeding of ALS-
linked proteins has not been shown conclusively in vivo. However,
the ﬁrst implication for the in vivo transmissibility of SOD1 pathol-
ogy was  recently reported (Ayers et al., 2014). In this study,
genetically vulnerable mice, expressing G85R-SOD1:YFP fusion
protein, were intraspinally injected with homogenates from ter-
minally sick, paralyzed mutant mice. The injected mice developed
motor neuron disease and exhibited a widespread redistribu-
tion of endogenous SOD1 to protein inclusions, found abundantly
throughout the spinal cord, brainstem and thalamus. While these
data strongly support the prion-like propagation of misfolded SOD1
in vivo, the lack of transmissibility to mice overexpressing wild-
type human SOD1 suggests that the process is extremely inefﬁcient
and depends on the loosening of the stable SOD1 dimeric structure
by the presence of the YFP tag.
Further supporting seeded aggregation and spread of misfolded
SOD1 in vivo, transgenic mutant human SOD1-expressing mice
presented accelerated disease progression and shorter lifespan
upon co-expression of wild type human SOD1 (hSOD1WT) (Deng
et al., 2006). Surprisingly, double-transgenic mice co-expressing
hSOD1WT with hSOD1A4V, the most aggressive SOD1 mutant in
humans, which does not cause disease in mice (Gurney et al., 1994),
resulted in ALS-like phenotype (Deng et al., 2006). The conversion
of unaffected to pathogenic phenotype may  be explained by prion-
like misfolding of human wild-type SOD1 by the A4V mutant in
the double-transgenic mouse. Indeed, disease in these mutant/wild
type co-expressing mice is accompanied by high levels of insol-
uble wild type SOD1, suggesting that misfolded, mutant SOD1
assemblies can recruit and convert wild type SOD1 to an aberrant
isoform, in a template-directed manner. Interestingly, transgenic
mice greatly overexpressing hSOD1WT were also shown to exhibit
SOD1 aggregation, neurotoxicity and shortened lifespan (Graffmo
et al., 2013). These data suggest that not only mutant, but also
wild type human SOD1, may  be involved in development of ALS in
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umans (Deng et al., 2006; Graffmo et al., 2013). It is also important
o note, that moderate overexpression of wild type human TDP-43
hTDP-43WT) in transgenic mice, also caused an ALS-like pheno-
ype, characterized by TDP-43 proteolytic cleavage, deposition of
ytoplasmic inclusions immunopositive for phosphorylated TDP-
3, axonal degeneration and early lethality (Xu et al., 2010). These
ice, however, do not fully recapitulate human ALS, as they do
ot develop fatal paralysis or protein aggregation in their nervous
ystem.
Taken together, the above studies indicate that prion-like seed-
ng of misfolded SOD1, TDP-43 and FUS proteins, may  drive the
athogenic pathways leading to neurotoxicity and neuronal cell
eath in ALS (Polymenidou and Cleveland, 2011).
. RNA binding and autoregulation promote prion-like
ropagation and toxicity
The mechanisms driving onset of ALS, as well as most of the
ther neurodegenerative disorders, remain unknown. Factors that
acilitate protein aggregation in subcellular compartments, such
s mutations that increase the aggregation propensity of the pro-
ein, are potential culprits. In the absence of identiﬁed genetic
ause, attractive candidates for disease triggers are environmental
timuli, such as cellular stressors that lead to protein–RNA gran-
le formation. Several types of RNA granules, such as processing
odies (P bodies), stress granules, or RNP transporting granules
ffer a possible model for aggregate nucleation and thereby, dis-
ase initiation. Under physiological conditions, such protein–RNA
omplexes are formed transiently in a strictly regulated manner
Buchan and Parker, 2009; Wolozin, 2012). However, under patho-
ogical conditions or due to chronic stress, these granules may  act
s precursors of the pathologic inclusions or pre-inclusions, which
ay  transform into irreversible dense aggregates that can act as
eeds of aggregation (Fig. 1B). Indeed, TDP-43 (Bentmann et al.,
012; Fujita et al., 2008; Liu-Yesucevitz et al., 2010; McDonald et al.,
011; Udan-Johns et al., 2014) and FUS (Bentmann et al., 2012;
ormann et al., 2010) are incorporated in cytoplasmic and nuclear
NA granules. Stress granules and other RNA granules are likely to
ct as sites of nucleation, due to the increase of local TDP-43 and FUS
oncentration, which could facilitate the initiation of their aggre-
ation. Moreover, the association with RNA in these granules may
otentiate the ordered aggregation of TDP-43 and FUS. Such scaf-
olding capacity of RNA was established via the in vitro aggregation
f the mammalian prion protein (Deleault et al., 2003), as gener-
tion of infectious prions with puriﬁed cellular prion protein has
een accomplished only by the addition of RNA and phospholipids
Wang et al., 2010). We  hypothesize that the RNAs naturally asso-
iated with TDP-43 and FUS might play a similar scaffolding role.
t is also conceivable that depending on the type of associated RNA
ithin the nucleating granules, various misfolded protein struc-
ures may  arise, possibly resulting in different aggregate subtypes.
dditionally, the pre-formed granules could play a toxic role by
equestering certain proteins and RNAs that are important for cell
iability.
TDP-43 was also shown to transiently form intranuclear aggre-
ates in response to heat shock (Udan-Johns et al., 2014). This
eaction was dependent on proteins from Hsp40/Hsp70 family,
hich interacted with the prion-like domain of TDP-43 and medi-
ted protein aggregation. The latter was shown to result in altered
nteraction with other RNA-binding proteins, such as hnRNPA1,
hich indicates that stress conditions, and consequently aggrega-ion, disrupt normal function of TDP-43 (Udan-Johns et al., 2014).
Importantly, both TDP-43 (D’Amico et al., 2013; Fujita et al.,
008; Liu-Yesucevitz et al., 2010) and FUS (D’Amico et al.,
013; Dormann et al., 2010) were found in stress granules Research 207 (2015) 94–105
observed in ALS patients. Additionally, they colocalized with the
stress granule marker TIA-1, another RNA-binding protein with a
prion-like domain that drives stress granule formation and organi-
zation (Wolozin, 2012). The cytoplasmic redistribution of TDP-43
(Colombrita et al., 2009; Dewey et al., 2011; Leggett et al., 2012; Liu-
Yesucevitz et al., 2010; McDonald et al., 2011) and FUS (Andersson
et al., 2008) and their association with stress granules could be reca-
pitulated in cell culture by induction of various cell stresses, such as
osmotic, oxidative or ER stress. Interestingly, these stress-induced
aggregates turned into irreversible pathological inclusions, as they
were shown to persist after removal of the stressor agent (Dewey
et al., 2011; Dormann et al., 2010). Furthermore, the association of
TDP-43 (Bentmann et al., 2012; Dewey et al., 2011; Liu-Yesucevitz
et al., 2010) and FUS (Bentmann et al., 2012) with stress gran-
ules depend on the presence of prion-like domain, as deletion
of this region inhibited the process. Also, mutations within this
domain resulted in enhanced stress granule formation kinetics and
increased granule size (Dewey et al., 2011; Dormann et al., 2010;
Ito et al., 2011; Liu-Yesucevitz et al., 2010).
Another protein property shared by TDP-43 and FUS that poten-
tially contributes to their self-perpetuating aggregation is the
autoregulatory pathway that controls their levels. The pre-mRNAs
encoding TDP-43 and FUS were identiﬁed among other targets
bound by TDP-43 and FUS proteins (Lagier-Tourenne et al., 2012;
Polymenidou et al., 2011). This binding leads to an autoregula-
tion mechanism controlling their protein levels through binding
of TDP-43 (Ayala et al., 2011; Polymenidou et al., 2011) and FUS
(Lagier-Tourenne et al., 2012; Zhou et al., 2013) to their own
transcripts and regulating the RNA processing pathway. After an
initiation phase, the formation of pre-inclusions containing mis-
folded TDP-43 or FUS would cause partial nuclear clearance, which
in turn would lead to increased levels of stable TARDBP or FUS trans-
cripts. Consequently, the levels of TDP-43 or FUS proteins would
also rise providing high level of substrate protein for seeded aggre-
gation, therefore contributing to growth of the pathogenic TDP-43
and FUS deposits. Taking into account that increased levels of TDP-
43 mRNA were observed in motor neurons from ALS patients (Rabin
et al., 2010), such feed-forward mechanism could explain the aggre-
gate propagation underlying ALS.
6. Non-cell autonomous toxicity
ALS is not only conﬁned in the spinal cord and the brain stem,
but it affects broadly the central nervous system (Geser et al.,
2008, 2009) and is mediated by non-cell autonomous mecha-
nisms (Boillee et al., 2006a; Ilieva et al., 2009). This means that
besides motor neurons, other types of neurons or glial cells are
also affected and contribute to ALS pathogenesis. Interestingly, glial
cells were shown to mediate ALS pathology through the release or
secretion of toxic factors (Boillee et al., 2006a; Yamanaka et al.,
2008). This non-cell autonomous mechanism was  recapitulated
in vitro, where mutant SOD1-expressing astrocytes were toxic to
co-cultured motor neurons (Di Giorgio et al., 2007, 2008). Impor-
tantly, this phenomenon was also observed for astrocytes derived
from familial and sporadic ALS patients (Haidet-Phillips et al., 2011;
Re et al., 2014). Furthermore, gray matter oligodendrocytes in
transgenic SOD1 mice presented pathogenic inclusions, prior to
the manifestation of clinical symptoms (Kang et al., 2013). In addi-
tion, a recently published study, reports on overlapping severity
of TDP-43 pathology in neurons and oligodentrocytes, in different
regions of the CNS in ALS patient samples. Interestingly, the gray
matter oligodendroglia with TDP-43 inclusions, were also iden-
tiﬁed in areas devoid of affected neurons (Brettschneider et al.,
2014). These observations imply that the gray matter oligoden-
drocyte pathology may  precede, and possibly trigger, pathology
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n neighboring neuronal cells in ALS (Brettschneider et al., 2014;
ang et al., 2013). Lastly, microglial cells are also likely contribu-
ors in pathogenesis, as deletion of mutant SOD1 within microglia
xtended disease progression in mice (Boillee et al., 2006b). In line
ith this, microglial pathology in ALS patient autopsy samples cor-
elates with disease progression and is linked to severity of motor
euron loss (Brettschneider et al., 2012).
Motor neurons are dependent on their neighboring glial cells,
hich are mainly responsible for neuronal metabolism support
Lee et al., 2012). Therefore, loss of physiological function of glial
ells in early ALS pathogenic events, could enhance motor neu-
on damage, not only through secretion of toxic agents, but also
y affecting neuron vulnerability and survival. Furthermore, the
athological changes in affected oligodendrocytes, which under
ormal conditions are responsible for formation of the myelin
heath, could explain the observed demyelination of neuronal
xons in ALS patients.
. Implication of prion-like spread for disease progression
The prion-like pathological protein propagation and neu-
oanatomic spread in ALS and other neurodegenerative dis-
ases provide a molecular mechanism for disease progression
Polymenidou and Cleveland, 2011). Indeed, in the recent years,
any studies supporting such mechanisms for propagation and
pread have been reported (Brettschneider et al., 2013, 2014;
avits, 2014; Ravits et al., 2007a, 2007b; Ravits and La Spada, 2009).
Correlation of clinical symptoms and motor neuron loss in
he neuraxis of ALS patients, showed focal and stochastic, loca-
ion of disease initiation within the nervous system (Ravits, 2014;
avits et al., 2007a, 2007b; Ravits and La Spada, 2009). At the
eginning of disease progression, the symptoms steadily worsen
ithin the initial focally affected region. Over time, the pathol-
gy (Brettschneider et al., 2014), and resulting motor impairment
Ravits et al., 2007a, 2007b) start to spread through the nervous sys-
em. The propagation of pathological lesions most probably occurs
ontiguously, through side-to-side connections, between proximal
egions (Ravits and La Spada, 2009). However, it is also conceiv-
ble that axonal transport and synaptic connections are involved
n the dissemination of pathological inclusions across the nervous
ystem (Brettschneider et al., 2013). The severity of neuronal loss
nd motor dysfunction is maximal in the focal body area and grad-
ally decreases outwards. Moreover, the site of initiation strongly
etermines the clinical manifestation of the disease (Ravits, 2014).
ogether, with the observation that initial symptoms occur in ran-
om locations in different patients, these characteristics of ALS
esult in heterogeneous phenotypes, namely: (I) primary lateral
clerosis predominantly affecting upper motor neurons (UMNs);
II) primary muscular atrophy, characterized predominantly by
egeneration of lower motor neurons (LMNs); (III) limb ALS char-
cterized mostly by degeneration of motor neurons important for
rm and leg function; and (IV) bulbar ALS, which affects neurons
mportant for speech and swallowing (Ravits, 2014).
In the most recent staging study, the distribution of neuronal
oss and phosphorylated TDP-43 (pTDP-43), a hallmark of ALS
athology, was mapped within the central nervous system of ALS
atients (Brettschneider et al., 2014). It was shown that the most
evere neuronal loss and aggregates containing pTDP-43 reside in
he dorsolateral motor nuclei columns of the cervical and lum-
osacral anterior horn. This suggests that these regions may  be the
arliest foci of TDP-43 pathology within the spinal cord. However, it
emains unclear, if the spinal cord lesions comprise the initial TDP-
3 nucleation sites or if they result from propagation of cortical
DP-43 pathological aggregates. Additionally, the molecular mech-
nisms of the release and uptake of seeds underlying the cell-to-cell
pread also remain to be characterized. Research 207 (2015) 94–105 101
Importantly, cell-to-cell propagation was  observed in cultured
cells transduced with TDP-43 (Nonaka et al., 2013) and SOD1
(Grad and Cashman, 2014; Münch et al., 2011) aggregates. SOD1
transmission is possibly based on SOD1 uptake from neighboring
cells through macropinocytosis (Grad and Cashman, 2014; Münch
et al., 2011) upon protein release to extracellular space from dying
cells, or through secretion of exosomes from living cells (Grad and
Cashman, 2014).
In conclusion, similarly to progression of prion diseases, motor
neuron loss (Ravits et al., 2007a, 2007b) and TDP-43 pathology
(Brettschneider et al., 2014) start focally in speciﬁc sites and, dur-
ing the progression of clinical disease, these pathological changes
spread across speciﬁc CNS regions in a spatiotemporal manner.
Future studies are needed to decipher the exact cellular and molec-
ular mechanisms underlying the initiation and progression of ALS
and the contribution of prion-like propagation to this process.
Importantly, understanding this contribution is of outmost impor-
tance, since it would offer possibilities of therapeutic interventions
by blocking protein aggregation and conversion, as well as with the
transport of protein aggregates from cell to cell.
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